Patents Issued in March 9, 2017
-
Publication number: 20170065499Abstract: Embodiments of the present invention are directed to methods and apparatus for the treatment of plaque, halitosis and other oral diseases in animals such as dogs. The methods and apparatus feature the administration of molecular iodine at a concentration that is effective and accepted by animals.Type: ApplicationFiled: September 8, 2016Publication date: March 9, 2017Inventor: James C. Richards
-
Publication number: 20170065500Abstract: The present invention is directed to an antiperspirant/deodorant composition comprising: hydrogen peroxide, wherein said composition is essentially free of aluminum cations or zirconium cations, and the composition is exposed to a light source having a wavelength range of >220 nm and <405 nm.Type: ApplicationFiled: September 9, 2015Publication date: March 9, 2017Inventors: Lorenzo Delpani, Heng Cai
-
Publication number: 20170065501Abstract: Nitride-based nanoparticles for use in sunscreen applications provided herein. A method includes selecting one or more nitride-based nanoparticles to serve as a core material in a sunscreen composition, wherein said selecting is based on a desired absorption spectrum of the sunscreen composition, and adjusting an amount of at least one element present within the nitride-based nanoparticles to achieve one or more user-defined optical characteristics with respect to the core material in the sunscreen composition. A composition includes one or more nitride-based nanoparticles constituting a core material in a sunscreen composition, wherein said nitride-based nanoparticles are selected based on a desired absorption spectrum of the sunscreen composition, and wherein an amount of at least one element present within the nitride-based nanoparticles is adjustable to achieve one or more user-defined optical characteristics.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065502Abstract: Zinc oxide compositions and methods for applying anti-reflective coating on oxide particles for sunscreen applications are provided herein. A method includes selecting one or more coating materials to be applied to zinc oxide particles in a sunscreen composition, wherein said selecting is based on optical properties of the coating materials, wherein the optical properties comprises at least the refractive index of each of the coating materials, and applying the selected coating materials to the zinc oxide particles to create the sunscreen composition. A composition includes multiple zinc oxide particles suspended within a medium forming sunscreen composition, and one or more coating materials applied to each of the zinc oxide particles, wherein each of the coating materials has a refractive index that is between the refractive index of air and the refractive index of zinc oxide, and wherein at least one of the coating materials incorporates a textured surface.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065503Abstract: Notch filter coatings for use in sunscreen applications are provided herein. An exemplary composition includes multiple zinc oxide particles suspended within a medium forming sunscreen composition; and a combination of multiple notch filter coating materials individually applied as a distinct layer to each of the multiple zinc oxide particles to create a multi-layered structure surrounding each of the multiple zinc oxide particles within the sunscreen composition, wherein the multi-layered structure: reflects light at a user-determined wavelength range based on the wavelength range at which each of the multiple notch filter coating materials reflects light; and allows wavelengths of light (i) within at least a portion of the ultraviolet spectrum and (ii) outside of the user-determined wavelength range to be absorbed by the multiple zinc oxide particles.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065504Abstract: Techniques for implementing organic materials in sunscreen applications are provided herein. A method includes selecting a combination of multiple organic materials to incorporate into a sunscreen composition, wherein said selecting is based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials, and incorporating the selected combination of organic materials into the sunscreen composition to generate the desired absorption spectrum. A composition includes a combination of multiple organic materials incorporated into a sunscreen composition, wherein the combination of organic materials is selected based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065505Abstract: Zinc oxide compositions and methods for controlling zinc oxide particle size for sunscreen applications are provided herein. A method includes manipulating the size of multiple zinc oxide particles to be below a maximum threshold; selecting one or more media to be used in a sunscreen composition, wherein said selecting is based on the refractive index of each of the media; and integrating the manipulated zinc oxide particles into the selected media to create the sunscreen composition. A composition includes multiple zinc oxide particles, wherein each of the zinc oxide particles is (i) coated with an optical coating material and (ii) of a size that is below a maximum threshold; and a medium layer within which the zinc oxide particles are suspended, wherein the medium layer comprises a mixture of one or more media, and wherein each of the media has a refractive index below a predetermined threshold.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065506Abstract: Zinc oxide compositions as well as techniques for doping ZnO particles for sunscreen applications are provided herein. A method includes selecting one or more dopants to be incorporated into one or more zinc oxide particles in a sunscreen composition, wherein the one or more dopants comprise chromium, cobalt, gallium, and/or tin, and wherein said selecting is based on one or more optical properties associated with each of the dopants, and incorporating the selected dopants into the zinc oxide particles to create the sunscreen composition. A composition includes multiple zinc oxide particles suspended within a medium forming sunscreen composition, and one or more dopants incorporated into each of the multiple zinc oxide particles, wherein the one or more dopants comprise chromium, cobalt, gallium, and/or tin, and wherein each of the dopants imparts one or more optical properties to the zinc oxide particle within which the dopant is incorporated.Type: ApplicationFiled: March 28, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065507Abstract: Zinc oxide compositions as well as techniques for plasmonic enhancement of zinc oxide light absorption for sunscreen applications are provided herein. One example method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles; and coating at least one portion of the surface of each of the one or more zinc oxide particles with the metal particles. Another example method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles; and blending the metal particles and the zinc oxide particles within a medium to create the sunscreen composition.Type: ApplicationFiled: April 29, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065508Abstract: Zinc oxide compositions as well as techniques for plasmonic enhancement of zinc oxide light absorption for sunscreen applications are provided herein. One example method includes selecting one or more metal particles to be used in conjunction with one or more zinc oxide particles in a sunscreen composition, wherein said selecting is based on the plasmon resonance frequency associated with each of the metal particles, and blending the metal particles and the zinc oxide particles within a medium to create the sunscreen composition.Type: ApplicationFiled: November 7, 2016Publication date: March 9, 2017Inventors: Talia S. Gershon, Ning Li, Devendra Sadana, Teodor K. Todorov
-
Publication number: 20170065509Abstract: There are provided black ginger extracts that contain reasonable amounts of methoxyflavones and which are reduced in undesirable flavors such as bitterness or in the intensity of a black purple color. To this end, oil or fat extracts are obtained from black ginger.Type: ApplicationFiled: May 1, 2015Publication date: March 9, 2017Inventor: Naoki KASAJIMA
-
Publication number: 20170065510Abstract: The sunscreen composition includes dibenzoylmethane derivative in 1 to 5% by weight of the composition, octyl-methoxycinnamate in 1 to 10% by weight of the composition and dermatologically acceptable excipients in 79 to 97% by weight of the composition containing 60-75% aqueous phase stabilised with 1-(4-methoxy-5-benzofuranyl)-3-phenyl 1, 3 propanedione (pongamol) in 0.9 to 6% by weight of the composition.Type: ApplicationFiled: March 27, 2015Publication date: March 9, 2017Inventors: Alain Victor KHAIAT, Shaju Asokan VAIKKATHUKATTIL, Ramesh Chandran KALAPPURAKKAL, Prakash Kumar UNNIKRISHNAN
-
Publication number: 20170065511Abstract: The invention relates to a conditioning preshave/aftershave composition and related method. The composition includes a microemulsion including 15%-25% of at least one alkyl(oligo)glycoside, 4%-10% of at least one mono- or diester of glycerol with at least one C10-C24 fatty acid as coemulsifier, and 15%-25% at least one oil, and 40%-66% water. The composition can be mixed a water-containing cosmetic carrier comprising: at least one alkyl ether phosphate or alkenyl ether phosphate of the formula (I).Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicant: Henkel AG & Co. KGaAInventors: Martina Kampmann, Barbara Heide
-
Publication number: 20170065512Abstract: A film forming composition comprises a first non-crosslinking polyamide/polyacrylate copolymer comprising at least one amide monomer; (meth)acrylate monomers; monomers having at least one carboxylic functional group; and monomers having at least one amine functional group. The film forming composition also comprises a second non-crosslinking polyamide copolymer comprising at least one amide; at least one quaternary ammonium containing monomer; and monomers having at least one amine functional group. Preferably, the film forming composition is essentially free of glycerin or glycerol.Type: ApplicationFiled: September 8, 2016Publication date: March 9, 2017Inventors: Yong Zhu, Gordon Gerald Guay
-
Publication number: 20170065513Abstract: A polymer composition providing improved curl benefits is disclosed. The composition includes a first weakly charged anionic polymer and a second weakly charged cationic polymer. When the polymer composition is applied to a Leneta card, the card has a minimum contraction of 10% as described by the “Contraction Test,” when the Leneta card is kept at a temperature in the range of 22 to 28° C. and at a relative humidity in the range of 40% to 50% to measure the contraction. Also, the first and second polymers are either water soluble or water dispersible and comprise from about 40% to about 99% identical chemical structure based on monomers in each polymer.Type: ApplicationFiled: September 8, 2016Publication date: March 9, 2017Inventors: Yong Zhu, Gordon Gerald Guay
-
Publication number: 20170065514Abstract: A cross-linked composition comprises the reaction product of an organohydrogensiloxane and a cross-linker, in the presence of a hydrosilylation catalyst. The organohydrogensiloxane comprises siloxy units of average formula (I): (R43SiO1/2)(R42—SiO2/2)a(R1R4SiO2/2)b(R4HSiO2/2)c(R2R4SiO2/2)d(R3R4SiO2/2)e—(R43Si—O1/2). Each of R1 and R2 is an independently selected hydrogen atom or a substituted or unsubstituted hydrocarbyl group. R3 is a hydrogen atom or a group having at least one carboxyl group or a precursor thereof. R4 is an independently selected substituted or unsubstituted hydrocarbyl group. Further, a?0, b?0, c?1, d?0, and e?1. The cross-linker has at least two aliphatic unsaturated hydrocarbon groups. A method of forming the cross-linked composition comprises the steps of providing the organohydrogensiloxane and cross-linker, and combining the organohydrogensiloxane and cross-linker in the presence of the hydrosilylation catalyst to form the cross-linked composition.Type: ApplicationFiled: April 24, 2015Publication date: March 9, 2017Inventors: Mary Kay Crofoot, Roxanne Haller, Donald Anthony Kadlec, Kimmai Thi Nguyen, Kenneth Edward Zimmerman
-
Publication number: 20170065515Abstract: Compositions, methods, and kits for cleansing, moisturizing, soothing, cooling, such as those, for example, that may be used to cleanse, moisturize, soothe, and cool the body or portions thereof.Type: ApplicationFiled: August 19, 2016Publication date: March 9, 2017Inventors: Brandon Joseph Karam, Jessica Karam Oley
-
Publication number: 20170065516Abstract: A cosmetic composition comprises a coffee cherry preparation, and most preferably an extract from a sub-ripe quick-dried coffee cherry. Particularly contemplated cosmetic compositions are formulated as a shampoo, lotion, cream, balm, or ointment, and will have at least one of an antioxidant effect, an anti-inflammatory effect, a UV-protective effect, an antimutagenic effect, a chemoprotective effect, a scar reducing effect, a skin-lightening effect, a moisturizing effect, a wrinkle reduction effect, and an antibacterial effect.Type: ApplicationFiled: November 18, 2016Publication date: March 9, 2017Inventor: Dusan Miljkovic
-
Publication number: 20170065517Abstract: The present invention provides novel compositions for the delivery of a hypnotic agent across the oral mucosa. In particular, the buffer system in the compositions of the present invention raises the pH of saliva to a pH greater than about 7.8, thereby facilitating the substantially complete conversion of the hypnotic agent from its ionized to its un-ionized form. As a result, the dose of hypnotic agent is rapidly and efficiently absorbed by the oral mucosa with surprisingly low inter-subject variability. Furthermore, delivery of the hypnotic agent across the oral mucosa advantageously bypasses hepatic first pass metabolism of the drug and avoids enzymatic degradation of the drug within the gastrointestinal tract. Methods for using the compositions of the present inversion for treating sleep disorders such as insomnia are also provided.Type: ApplicationFiled: March 10, 2016Publication date: March 9, 2017Applicant: PARATEK PHARMACEUTICALS, INC.Inventor: Nikhilesh N. SINGH
-
Publication number: 20170065518Abstract: The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicant: CHIESI FARMACEUTICI S.P.A.Inventors: DAVID ANDREW LEWIS, BRIAN JOHN MEAKIN, GAETANO BRAMBILLA
-
Publication number: 20170065519Abstract: Composite structures composed of a fibril core and a polymeric coat and designed capable of encapsulating both hydrophobic and hydrophilic bioactive agents while retaining the activity of these agents are disclosed. Further disclosed are processes of preparing such composite structures, and medical devices and disposable articles made therefrom.Type: ApplicationFiled: August 11, 2016Publication date: March 9, 2017Applicant: Ramot at Tel-Aviv University Ltd.Inventor: Meital ZILBERMAN
-
Publication number: 20170065520Abstract: A stable liposomal formulation for treating cancer. The formulation includes liposomes containing one or more of POPC, DMPC, and DOPC and one or more of the anti-cancer drugs sirolimus, umirolimus, and everolimus encapsulated in the liposomes. Also provided are efficient remote film loading methods for loading the liposomes with the anti-cancer drugs and methods for treating cancer with the liposomal formulations.Type: ApplicationFiled: September 9, 2015Publication date: March 9, 2017Inventors: Ting-Bin Yu, Zhiwei Shi, Shih-Horng Su
-
Publication number: 20170065521Abstract: Drug delivery systems are disclosed which include a drug in dry powder form and a biodegradable or metabolizable carrier having an average particle size of less than about 1 mm for delivery of the drug to a particular location in the body and for providing for the timed elution of the drug at that location, preferably by exhibiting a linear drug elution profile for a sustained drug release period of at least 30 days. Methods for manufacturing these drug delivery systems are also disclosed.Type: ApplicationFiled: September 9, 2016Publication date: March 9, 2017Applicant: Micell Technologies, Inc.Inventor: Wenda C. Carlyle
-
Publication number: 20170065522Abstract: Disclosed herein are pharmaceutical compositions comprising a plurality of first beads each comprising: a core; a first layer comprising pilocarpine or a pharmaceutically acceptable salt thereof; and a second layer comprising a first polymer. Also disclosed are pharmaceutical compositions comprising a plurality of second beads each comprising: a core; and a first layer comprising tolterodine or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical formulations comprising: a) a plurality of the first beads; b) a plurality of the second beads; or c) a plurality of the first beads and a plurality of the second beads.Type: ApplicationFiled: July 6, 2016Publication date: March 9, 2017Inventors: Mehdi PABORJI, Robert V. Tuohy, III, Peter R.P. Freed, Roger S. FLUGEL
-
Publication number: 20170065523Abstract: In one aspect, compositions comprising a population of core-shell nanoparticles are described herein. In some cases, the population of core-shell nanoparticles comprises a core component and a shell component encapsulating or surrounding the core component. Additionally, one or more radiosensitizers are disposed in or dispersed throughout the core component, or an interior region of the core component. Similarly, one or more chemotherapeutic agents are disposed in or dispersed throughout the shell component, or an interior region of the shell component. Moreover, in some cases, the core component is formed from one or more biodegradable polymers. Further, in some instances, the shell component is formed from one or more stimuli responsive polymers, such as a temperature-responsive polymer and/or pH-responsive polymer.Type: ApplicationFiled: September 9, 2016Publication date: March 9, 2017Inventors: Kytai NGUYEN, Jyothi Menon, Debabrata Saha
-
Publication number: 20170065524Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20170065525Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Applicants: The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20170065526Abstract: The present invention discloses a pharmaceutical composition that includes rivaroxaban and one or more excipient in a solid dosage form and methods for making the same. Methods for making compositions of the present invention includes powderizing rivaroxaban by centrifugal wet granulation to form compositions suitable for solid oral dosage form. Pharmaceutical dosage forms produced by methods of the present invention are more homogenous, smoother, and have better rheological properties, better compressibility, and much easier to make. They are much lower in cost and also easier to produce at industrial scales.Type: ApplicationFiled: September 7, 2016Publication date: March 9, 2017Inventors: Shaoping Wang, Xin Liu, Meng Wang, Weining Yang, Kwok Chow
-
Publication number: 20170065527Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: ApplicationFiled: September 13, 2016Publication date: March 9, 2017Applicants: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. MCKENNA, Richard O. MANNION, Edward P. O'DONNELL, Haiyong H. HUANG
-
Publication number: 20170065528Abstract: The invention provides an enteric film coating comprising a salt of alginic acid and aqueous shellac, wherein the enteric film coating is alcohol resistant.Type: ApplicationFiled: March 3, 2015Publication date: March 9, 2017Inventor: Brian Kai-ming CHENG
-
Publication number: 20170065529Abstract: The present invention relates to a pharmaceutical dosage form delivering an immediate release profile containing the active substance 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate.Type: ApplicationFiled: September 9, 2015Publication date: March 9, 2017Inventors: Roman MESSERSCHMID, Peter LACH, Thorsten SOKOLIESS, Peter STOPFER, Dirk TROMMESHAUSER
-
Publication number: 20170065530Abstract: The present invention is directed to compositions and methods of delivery of CoQ that is reduced in the presence of lipoic acid and, optionally a fatty acid and/or optionally in a monoterpene. The compositions that include the reduced CoQ can be formulated in soft gel capsules.Type: ApplicationFiled: May 20, 2016Publication date: March 9, 2017Inventor: Michael Fantuzzi
-
Publication number: 20170065531Abstract: A sustained release oral pharmaceutical form suitable for single daily dose administration has a neutral microgranule coated with a mounting layer of active ingredient and pharmaceutically acceptable binder; and a coating layer of a hydrophobic coating polymer of a non-water soluble cellulose derivative, and at least 20% of inert load in relation to dry weight of hydrophobic coating polymer. The pharmaceutical form has improved resistance to rapid release of active ingredient, particularly in the presence of alcohol.Type: ApplicationFiled: March 11, 2015Publication date: March 9, 2017Inventors: Catherine HERRY, Laury Trichard
-
Publication number: 20170065532Abstract: The present invention generally relates to compositions and methods for delivering a vaccine. The compositions and methods disclosed herein are particularly useful in making prophylactic and therapeutic vaccines.Type: ApplicationFiled: March 4, 2015Publication date: March 9, 2017Applicant: ORBIS HEALTH SOLUTIONS, LLCInventor: Thomas E. Wagner
-
Publication number: 20170065533Abstract: The present invention relates to a poly(lactic glycolic) acid (PLGA) nanoparticle associated with therapeutic agents for a variety of therapeutic applications.Type: ApplicationFiled: September 12, 2016Publication date: March 9, 2017Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.Inventors: Simon BENITA, Taher NASSER, Nour KARRA, Amit BADIHI
-
Publication number: 20170065534Abstract: The present invention relates, generally, to compositions comprising at least one antigen encapsulated within at least one fibrous polymer matrix and their use in intradermal vaccine delivery. It has been discovered that the intradermal delivery of antigens into the antigenpresenting cell-rich layers of the skin requires less antigen than traditional vaccine delivery methods and is still capable of eliciting an immune response comparable to that observed with traditional vaccine delivery methods.Type: ApplicationFiled: May 1, 2015Publication date: March 9, 2017Applicant: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORKInventors: Katarzyna SAWICKA, Sanford SIMON
-
Publication number: 20170065535Abstract: A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent.Type: ApplicationFiled: April 6, 2016Publication date: March 9, 2017Applicant: NOVEN PHARMACEUTICALS, INC.Inventor: DAVID KANIOS
-
Publication number: 20170065536Abstract: A method of treating a host of neuromuscular, neurodegenerative, developmental, autoimmune and metabolic diseases/disorders related to aging, such as traumatic injury, stroke, Huntington's disease, Epilepsy, Multiple Sclerosis (MS), Lupus, Type-1 and Type-2 diabetes, Maturity Onset Diabetes of the Young (MODY), myasthenia gravis (MG), rheumatoid arthritis (RA), Graves' disease, Guillain-Barré syndrome (GBS), metabolic syndrome, Muscular Dystrophy or Duchenne Muscular Dystrophy (DMD), severe burns, aging, Amyotrophic Lateral Sclerosis (ALS), Friedreich's Ataxia, Batten Disease, Alzheimer's disease, optic neuritis, Leber's hereditary optic neuropathy (LHON), autism, Rett syndrome, Batten Disease, Angelman's Syndrome, Leigh disease, Fragile-X Syndrome, depression, Parkinson's disease, mitochondrial diseases, developmental disorders, metabolic disease disorders and/or autoimmune disorders by inducing endogenous BDNF expression with DNP treatment to protect from neuromuscular dysfunction/disorders and/or neurodegeType: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Applicant: Mitochon Pharmaceuticals, Inc.Inventors: Robert ALONSO, John Gerard GEISLER
-
Publication number: 20170065537Abstract: The invention relates to a method for producing a flurane complex, comprising the following steps: producing an aqueous solution of sulfobutylether-?-cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of from 2 to 15° C.; adding the flurane to the aqueous solution; allowing the solution to react to produce the complex; and separating the complex.Type: ApplicationFiled: February 26, 2015Publication date: March 9, 2017Inventors: Norbert Roewer, Jens Broscheit
-
Publication number: 20170065538Abstract: The present invention relates to methods for the treatment or prevention of fatigue associated with disordered sleep, for example, in multiple sclerosis, fibromyalgia, Fabry's disease, Parkinson's disease, or traumatic brain injury, using cyclobenzaprine The present invention further relates to a biomarker for the therapeutic effects of a cyclobenzaprine treatment.Type: ApplicationFiled: September 15, 2016Publication date: March 9, 2017Inventors: Seth Lederman, Herb Harris
-
Publication number: 20170065539Abstract: Methods of shortening the duration of anti-infective therapy and increasing the effectiveness of anti-infective drugs in subjects with infection are present. The methods are based on altering the replication rate of a pathogen, which makes the pathogen more susceptible to the actions of the anti-infective drug.Type: ApplicationFiled: January 26, 2016Publication date: March 9, 2017Applicant: INSTITUTE FOR CLINICAL PHARMACODYNAMICS, INC.Inventor: Paul G. Ambrose
-
Publication number: 20170065540Abstract: Provided herein are compositions and methods for treating or preventing infection.Type: ApplicationFiled: November 21, 2016Publication date: March 9, 2017Applicants: UNIVERSITY OF ROCHESTER, UNIVERSITY OF KANSASInventors: Paul M. Dunman, Damian J. Krysan, Daniel P. Flaherty
-
Publication number: 20170065541Abstract: The synthesis, growth inhibition and radioprotective activity of the PrC-210 aminothiol, 3-(methyl-amino)-2-((methylamino)methyl)propane-1-thiol, and its polyamine and thiolated polyamine progenitors are reported. All of the molecules significantly inhibited growth of cultured normal human fibroblasts. The combination of an ROS-scavenging thiol group and a positively charged alkyl-amine backbone provided the most radioprotective aminothiol molecule.Type: ApplicationFiled: August 30, 2016Publication date: March 9, 2017Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventor: William E. Fahl
-
Publication number: 20170065542Abstract: The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ?-(methylsulfonyl)alkylamine or ?-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ?-(methylsulfonyl)alkylamine or ?-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.Type: ApplicationFiled: September 9, 2016Publication date: March 9, 2017Inventors: Joseph P. ST. LAURENT, Gerald S. JONES, David M. BRESSE
-
Publication number: 20170065543Abstract: The present inventions concerns derivatives of aminocyclobutane, particularly as NMDA receptor antagonists, their application in human therapy and their method of preparation. These compounds correspond to the general formula (1): wherein: X1 represents a hydrogen atom or fluorine atom; X2 is a hydrogen atom or fluorine atom or chlorine atom; R1 represents a hydrogen atom or fluorine atom or chlorine atom or methyl group or methoxy group or cyano group; R2 represents independently or together a methyl group or ethyl group.Type: ApplicationFiled: September 12, 2016Publication date: March 9, 2017Applicant: PIERRE FABRE MEDICAMENTInventors: Bernard VACHER, Elodie BLANC, Ronan DEPOORTERE
-
Publication number: 20170065544Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting or treating idiopathic pulmonary fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.Type: ApplicationFiled: April 21, 2016Publication date: March 9, 2017Applicant: MediciNova, Inc.Inventors: Kazuko MATSUDA, Yuichi IWAKI
-
Publication number: 20170065545Abstract: Methods useful for reducing or preventing hepatic steatosis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or PDE5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.Type: ApplicationFiled: February 27, 2015Publication date: March 9, 2017Inventors: Michael ZEMEL, Antje BRUCKBAUER
-
Publication number: 20170065546Abstract: The present invention concerns a food supplement comprising Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds as well as finished food products comprising the food supplement. The present invention further concerns a nutraceutical or cosmetic preparation comprising as an active ingredient Salvia sclarea seeds, or flour, oil or pulp or extracts obtained from the seeds.Type: ApplicationFiled: November 17, 2016Publication date: March 9, 2017Inventors: Nativ DUDAI, Zohara YANIV BACHARACH, Eli PUTIEVSKY, Diah SAADI, Dan SCHAFFERMAN, David CHAIMOVITSH
-
Publication number: 20170065547Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.Type: ApplicationFiled: October 27, 2016Publication date: March 9, 2017Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
-
Publication number: 20170065548Abstract: An isothiocyanate functional surfactant, wherein the protonated form of said surfactant is represented by the following chemical structure: wherein X includes an integer ranging from approximately 1 to approximately 25, and wherein Y includes an integer ranging from approximately 6 to approximately 25.Type: ApplicationFiled: November 16, 2016Publication date: March 9, 2017Inventor: Michael E. Silver